Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

NCT01607346 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01607346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01607346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Terminated
Start date
March 27, 2013
Completion date
November 16, 2016
Enrollment
10 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy